160 related articles for article (PubMed ID: 18819481)
1. [Preparation and in vitro corneal retention behavior of novel cationic microemulsion/in situ gel system].
Ma SW; Gan Y; Gan L; Zhu CL; Zhu JB
Yao Xue Xue Bao; 2008 Jul; 43(7):749-55. PubMed ID: 18819481
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies on ocular vitamin A palmitate cationic liposomal in situ gels.
He W; Guo X; Feng M; Mao N
Int J Pharm; 2013 Dec; 458(2):305-14. PubMed ID: 24409520
[TBL] [Abstract][Full Text] [Related]
3. [Ion-sensitive nanoemulsion-in situ gel system for ophthalmic delivery of flurbiprofen axetil].
Shen JQ; Gan Y; Gan L; Zhu CL; Zhu JB
Yao Xue Xue Bao; 2010 Jan; 45(1):120-5. PubMed ID: 21351461
[TBL] [Abstract][Full Text] [Related]
4. Ocular delivery of cyclosporine A based on glyceryl monooleate/poloxamer 407 liquid crystalline nanoparticles: preparation, characterization, in vitro corneal penetration and ocular irritation.
Chen Y; Lu Y; Zhong Y; Wang Q; Wu W; Gao S
J Drug Target; 2012 Dec; 20(10):856-63. PubMed ID: 23050903
[TBL] [Abstract][Full Text] [Related]
5. Design and evaluation of thermoreversible in situ gelling system of forskolin for the treatment of glaucoma.
Gupta S; Samanta MK
Pharm Dev Technol; 2010; 15(4):386-93. PubMed ID: 19772380
[TBL] [Abstract][Full Text] [Related]
6. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel.
Gratieri T; Gelfuso GM; de Freitas O; Rocha EM; Lopez RF
Eur J Pharm Biopharm; 2011 Oct; 79(2):320-7. PubMed ID: 21641994
[TBL] [Abstract][Full Text] [Related]
7. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers.
Li X; Nie SF; Kong J; Li N; Ju CY; Pan WS
Int J Pharm; 2008 Nov; 363(1-2):177-82. PubMed ID: 18706987
[TBL] [Abstract][Full Text] [Related]
8. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results.
Gan L; Gan Y; Zhu C; Zhang X; Zhu J
Int J Pharm; 2009 Jan; 365(1-2):143-9. PubMed ID: 18773948
[TBL] [Abstract][Full Text] [Related]
9. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery.
Gratieri T; Gelfuso GM; Rocha EM; Sarmento VH; de Freitas O; Lopez RF
Eur J Pharm Biopharm; 2010 Jun; 75(2):186-93. PubMed ID: 20188828
[TBL] [Abstract][Full Text] [Related]
10. A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties.
Mayol L; Quaglia F; Borzacchiello A; Ambrosio L; La Rotonda MI
Eur J Pharm Biopharm; 2008 Sep; 70(1):199-206. PubMed ID: 18644705
[TBL] [Abstract][Full Text] [Related]
11. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.
Patel N; Nakrani H; Raval M; Sheth N
Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408
[TBL] [Abstract][Full Text] [Related]
12. Formulation and development of ophthalmic in situ gel for the treatment ocular inflammation and infection using application of quality by design concept.
Patel N; Thakkar V; Metalia V; Baldaniya L; Gandhi T; Gohel M
Drug Dev Ind Pharm; 2016 Sep; 42(9):1406-23. PubMed ID: 26716613
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide.
Guinedi AS; Mortada ND; Mansour S; Hathout RM
Int J Pharm; 2005 Dec; 306(1-2):71-82. PubMed ID: 16263229
[TBL] [Abstract][Full Text] [Related]
14. Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: ex-vivo transcorneal permeation, corneal toxicity and irritation testing.
Pathak MK; Chhabra G; Pathak K
Drug Dev Ind Pharm; 2013 May; 39(5):780-90. PubMed ID: 22873799
[TBL] [Abstract][Full Text] [Related]
15. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study.
Singh J; Chhabra G; Pathak K
Drug Dev Ind Pharm; 2014 Sep; 40(9):1223-32. PubMed ID: 23837522
[TBL] [Abstract][Full Text] [Related]
16. Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin: development, characterization, in vitro permeation and in vivo pharmacokinetic studies.
Liu R; Sun L; Fang S; Wang S; Chen J; Xiao X; Liu C
Pharm Dev Technol; 2016 Aug; 21(5):576-82. PubMed ID: 26024239
[TBL] [Abstract][Full Text] [Related]
17. Controlled release of vitamin A palmitate from crosslinked cyclodextrin organic framework for dry eye disease therapy.
Ye X; Li F; Li M; Zhang G; Wang W; Wang Z; Zhang H; Dong L; Lin X; Wu L; Peng C; Wang L; Chen W; Zhang J
Int J Pharm; 2024 Jun; 659():124279. PubMed ID: 38806096
[TBL] [Abstract][Full Text] [Related]
18. Thermoreversible in situ gelling poloxamer-based systems with chitosan nanocomplexes for prolonged subcutaneous delivery of heparin: design and in vitro evaluation.
Radivojša M; Grabnar I; Ahlin Grabnar P
Eur J Pharm Sci; 2013 Sep; 50(1):93-101. PubMed ID: 23524253
[TBL] [Abstract][Full Text] [Related]
19. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits.
Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH
Int J Pharm; 2013 Feb; 443(1-2):293-305. PubMed ID: 23333217
[TBL] [Abstract][Full Text] [Related]
20. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system.
Gupta H; Jain S; Mathur R; Mishra P; Mishra AK; Velpandian T
Drug Deliv; 2007 Nov; 14(8):507-15. PubMed ID: 18027180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
